<DOC>
	<DOCNO>NCT00246701</DOCNO>
	<brief_summary>The purpose OM6 evaluate efficacy safety Lovaza ( omega-3-acid ethyl ester ) [ formerly know Omacor ] combine simvastatin lower non-high-density lipoprotein cholesterol ( non-HDL-C ) subject persistent high triglyceride despite statin therapy . Additionally , two-year extension trial ( LOV111818/OM6X ) post NCT00903409 .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Combined Omacor ( Omega-3-acid Ethyl Esters ) Simvastatin Therapy Hypertriglyceridemic Subjects</brief_title>
	<detailed_description>Two study comprise OM6 Program . Study OM6 / LOV111858 ( double-blind study ) require post result base FDAAA . Study OM6X / LOV111818 ( open-label extension ) post NCT00903409 .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Men woman age 1879 year , inclusive Current therapy statin drug Triglyceride level 200 499 mg/dL Normally active good health basis medical history , brief physical examination , electrocardiogram , routine laboratory test Provide write informed consent authorization protect health information disclosure Sensitivity statin drug omega3 fatty acid Lipoprotein lipase impairment apo C2 deficiency type III hyperlipidemia Unexplained muscle pain weakness History pancreatitis Recent history certain heart , kidney , liver , lung , gastrointestinal disease , cancer ( except nonmelanoma skin cancer ) Poorly control diabetes , receive insulin therapy Pregnant lactating female . Women childbearing potential use medically approve method contraception . Use certain type hormone , anticonvulsant drug , immunologic drug , antibiotic , antifungal antiviral drug , cardiac drug Use warfarin ( Coumadin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>omega-3-acid ethyl ester</keyword>
	<keyword>simvastatin</keyword>
	<keyword>Lovaza</keyword>
	<keyword>High triglyceride</keyword>
</DOC>